阿奇霉素联合莫沙必利治疗糖尿病胃轻瘫的疗效及安全性观察

Efficacy and Safety of Azithromycin Combined with Mosapride in Patients with Diabetic Gastroparesis

目的:探讨阿奇霉素与莫沙必利联合治疗糖尿病胃轻瘫的疗效及安全性。方法:糖尿病胃轻瘫患者70例随机分为观察组和对照组。两组患者均予药物控制血糖(胰岛素注射或降糖药口服)。观察组患者予阿奇霉素肠溶片0.25 g,po,qd,莫沙必利片5 mg,po,tid联合治疗,对照组患者予单纯莫沙必利片5 mg,po,tid治疗,两组疗程均为4周。观察两组患者治疗后的临床疗效及药物不良反应,比较治疗后随访1年的复发率。结果:治疗4周后,观察组临床总有效率明显高于对照组(94.29%vs.77.14%,P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。随访1年,观察组复发率明显低于对照组(P<0.05)。结论:阿奇霉素与莫沙必利联合治疗糖尿病胃轻瘫疗效肯定,安全性较好,并能有效降低患者的复发率。

Objective：To explore the efficacy and safety of azithromycin combined with mosapride in the patients with diabetic gastroparesis （ DGP） . Methods：Totally 70 cases of patients with DGP were randomly divided into the observation group and the control group. All the patients were given drugs to control the blood sugar （ injection of insulin or oral administration of hypoglycemic drugs） . The patients in the observation group were given azithromycin enteric-coated tablets 0. 25g per time, once a day, and mosapride tablets 5mg per time, three times a day, while the patients in the control group were only given mosapride tablets 5mg per time, three times a day. The treatment course was 4 weeks. The clinical curative effect and drug adverse reactions （ ADR） in the two groups after the med-ical treatment were observed, and the reoccurrence rate after one-year following-up was compared as well. Results： After the 4-week treatment, the total clinical efficiency in the observation group was much higher than that in the control group （94. 29% vs. 77. 14%, P〈0. 05）. The incidence of ADR in the two groups showed no statistical difference （P〉0. 05）. The reoccurrence rate in the observa-tion group was much lower than that in the control group （P〈0. 05）. Conclusion：Azithromycin combined with mosapride shows reli-able curative effect in the patients with DGP with high security, which can effectively reduce the reoccurrence rate of the patients.